What is the primary purpose of this SEC filing?

This filing is a Form 10-Q, which is a quarterly report required by the U.S. Securities and Exchange Commission (SEC) for publicly traded companies. It provides an update on the company's financial performance and condition during the third quarter of 1998.

Where can I find the actual financial statements and detailed performance data for Merck for this period?

The text provided is a directory listing from the SEC's EDGAR database and does not contain the actual financial statements or detailed operational analysis. To access the full report, you would need to locate and view the complete 10-Q filing document itself, which contains detailed financial tables and management discussions.

What kind of information is typically included in a Merck 10-Q filing from this era?

A typical 10-Q filing from Merck in 1998 would include unaudited financial statements (consolidated balance sheets, statements of income, and statements of cash flows), a management's discussion and analysis (MD&A) of financial condition and results of operations, and disclosures about legal proceedings and risk factors. Investors would look for details on sales of key products, R&D investments, and any significant business developments.

What does the filing date of November 8, 1998, signify?

The filing date of November 8, 1998, indicates when Merck submitted its quarterly report for the period ending September 29, 1998, to the SEC. This suggests the company met its regulatory deadline for reporting its third-quarter financial results.

MRK 10-Q Quarterly Report Q3 FY1998 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc.'s 10-Q filing for the period ending September 29, 1998, provides a snapshot of the company's financial performance during the third quarter of that year. While the provided text is primarily navigational information for the SEC Edgar database and does not contain detailed financial statements, it indicates a standard quarterly reporting process. Investors would typically look for key metrics such as revenue, net income, earnings per share, and trends in sales of major products. The filing also would normally include management's discussion and analysis of financial condition and results of operations, offering insights into the drivers of performance and future outlook. As this is a preliminary filing notification, specific financial figures and operational details are not present. However, for investors, the significance lies in confirming that Merck is meeting its reporting obligations and that subsequent detailed filings (like the actual financial statements within the 10-Q) would provide the necessary data to assess the company's ongoing health and strategic progress. The period covered by this report would have been crucial for evaluating the company's standing in the pharmaceutical market and its ability to navigate the competitive landscape of the late 1990s.

Key Highlights

1Merck & Co., Inc. filed its 10-Q quarterly report for the period ending September 29, 1998.
2The filing date was November 8, 1998, indicating timely reporting.
3The provided text is a directory listing for the filing within the SEC EDGAR system, not the financial report itself.
4Investors would expect to find key financial data, such as revenue, profit, and earnings per share, within the full 10-Q document.
5Management's Discussion and Analysis (MD&A) would typically offer insights into operational performance and strategic initiatives.
6This filing serves as confirmation of Merck's adherence to regulatory reporting requirements for the third quarter of 1998.
7Specific financial performance details and product sales figures are not accessible from the provided text.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 1998

Summary

Key Highlights

Frequently Asked Questions